DexCom investors sued over alleged securities fraud and design flaws.

Pomerantz LLP is investigating DexCom, Inc. for potential securities fraud and unlawful business practices. A short report by Hunterbrook Media alleged that Dexcom made unauthorized design changes to its G7 continuous glucose monitoring system, leading to inaccurate readings and hospitalizations/deaths. Following this news, Dexcom's stock price fell 11.76%. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

DexCom Inc. (DXCM) has been under intense scrutiny following allegations of unauthorized design changes to its G7 continuous glucose monitoring (CGM) system, which has led to inaccurate readings and severe health consequences. The company's stock price has plummeted in response to these revelations, with shares falling by 11.76% since the news broke. Pomerantz LLP is now investigating DexCom for potential securities fraud and unlawful business practices, with investors advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The allegations, first reported by Hunterbrook Media, allege that DexCom made an unauthorized design change to the G7 sensors in December 2023. This change involved replacing the coating with an internal formulation, despite the company's own tests showing it to be inferior in every accuracy metric. The device was marketed despite these findings, leading to inaccurate readings and severe health issues for users.

Several high-profile incidents have been cited, including the death of a six-year-old girl, Billy Sosbe, and a driver who fainted due to a lack of hypoglycemia alerts. These incidents have fueled a Facebook group with nearly 60,000 members, and some endocrinologists report disproportionate inaccuracies and repeated failures. The competitive landscape is also challenging DexCom, with competitors like Abbott claiming greater accuracy with their products and the market becoming more complex with the advent of GLP-1 treatments and potential Medicare coverage for CGMs.

The company has faced significant internal upheaval, with several executives, including the CEO Kevin Sayer, leaving amid the FDA's scrutiny. The new CEO is the son-in-law of a former CEO, raising questions about the company's governance structure.

Financially, DexCom has faced challenges, with aggressive tactics leading to the company exceeding consensus estimates in the second quarter. However, indicators have deteriorated, with an average collection period exceeding 100 days and a gross margin falling to 59.5% in Q2, marking 15 consecutive quarters of annual decline. Hunterbrook Capital, the investment fund arm of the group, has declared a short position in DexCom, contributing to the stock's fall.

Investors are advised to stay informed about the ongoing investigations and potential regulatory actions. For updates and corrections, email newsroom[at]stocktwits[dot]com.